3 recruiting, 1 completed. 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Exegi Pharma, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA) - HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma | Phase 2 | Recruiting | University of California, San Francisco | 90 | 2026-09-04 | 2026-10-29 |
| Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) EXE-346, Placebo - Ileal Pouch | Phase 1 / Phase 2 | Recruiting | Exegi Pharma, LLC | 50 | 2023-11-06 | 2026-05-28 |
| The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study Probiotic Supplement, Transcutaneous Vagal Nerve Stimulation (tVNS) - Cognition, Gut Microbiome | Not applicable | Recruiting | University of Florida | 80 | 2022-06-01 | 2026-08-06 |
| Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers Visbiome Extra Strength, Placebo - HIV-1 Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 93 | 2016-04-01 | 2020-01-06 |
Pouchitis (1) · Squamous Intraepithelial Lesions (1)
Probiotics (1)
United States (4) · Puerto Rico (2)
Adriana Andrade, MD, MPH (1) · Edgar T Overton, MD (1) · Eric Porges, PhD (1) · Joel Palefsky, MD (1) · Julia Collins, MS (1) · Robert L Cook, MD (1)
P01AA029543 (1), U01AI068636 (1), U24CA275417 (1)